{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:58:58Z","timestamp":1785430738397,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009830","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,11,27]],"date-time":"2016-11-27T00:00:00Z","timestamp":1480204800000}}],"reference-count":78,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009830.pub2","type":"journal-article","created":{"date-parts":[[2016,11,27]],"date-time":"2016-11-27T14:21:04Z","timestamp":1480256464000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Haloperidol for long-term aggression in psychosis"],"prefix":"10.1002","volume":"2016","author":[{"given":"Abha","family":"Khushu","sequence":"first","affiliation":[{"name":"Watford General Hospital; Paediatrics; Vicarage Road Watford Hertfordshire UK WD18 0HB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J","family":"Powney","sequence":"additional","affiliation":[{"name":"The University of Manchester; Department of Clinical Psychology; 2nd Floor, Zochonis Building Brunswick Street Manchester UK M13 9PL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,27]]},"reference":[{"key":"10.1002\/14651858.CD009830.pub2-BIB0002|cit1","unstructured":"Krakowski M Czobor P A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine and haloperidol 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain 2009"},{"issue":"1-3","key":"10.1002\/14651858.CD009830.pub2-BIB0001|cit2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2009.02.006","article-title":"Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol","volume":"110","author":"Krakowski","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0009|cit3","unstructured":"Krakowski MI Clozapine and olanzapine in violent schizophrenics CRISP database (www-commons.cit.nih.gov\/crisp\/index.html)"},{"issue":"2","key":"10.1002\/14651858.CD009830.pub2-BIB0005|cit4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JCP.0b013e3181d47b5e","article-title":"A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine, and haloperidol","volume":"30","author":"Krakowski","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0006|cit5","doi-asserted-by":"crossref","unstructured":"Krakowski MI Czobor P Depression and impulsivity as pathways to violence: implications for antiaggressive treatment Schizophrenia Bulletin 2014 886 94","DOI":"10.1093\/schbul\/sbt117"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0007|cit6","doi-asserted-by":"crossref","unstructured":"Krakowski MI Czobor P Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial Journal of Clinical Psychiatry 2012 74 80","DOI":"10.4088\/JCP.11m07238"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0008|cit7","doi-asserted-by":"crossref","unstructured":"Krakowski MI Czobor P Neurocognitive impairment limits the response to treatment of aggression with antipsychotic agents Schizophrenia Bulletin 2011 311 2","DOI":"10.1037\/e554362012-064"},{"issue":"6","key":"10.1002\/14651858.CD009830.pub2-BIB0003|cit8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","article-title":"Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Krakowski","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD009830.pub2-BIB0004|cit9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0b013e3181855cd6","article-title":"Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients","volume":"28","author":"Krakowski","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009830.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0165-1781(81)90046-9","article-title":"Aggression control and structuring of social relations among recently admitted schizophrenics","volume":"5","author":"Singh","year":"1981","journal-title":"Psychiatry Research"},{"issue":"6","key":"10.1002\/14651858.CD009830.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder","volume":"159","author":"Bilder","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD009830.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0924-977X(01)80300-X","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder","volume":"11","author":"Bilder","year":"2001","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Bilder RM Goldman RS Volavka J Czobor P Hoptman M Sheitman B Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder Schizophrenia Research 2002 194","DOI":"10.1016\/S0924-977X(01)80300-X"},{"issue":"11","key":"10.1002\/14651858.CD009830.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1176\/appi.ps.52.11.1510","article-title":"Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia","volume":"52","author":"Citrome","year":"2001","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0015|cit15","unstructured":"Citrome LL Volavka J Czobor P Nolan K Lieberman JA Lindenmayer JP Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco (CA) 2003"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0016|cit16","unstructured":"Citrome LL Volavka J Czobor P Sheitman BB Lindenmayer JP McEvoy JP Atypical antipsychotics and hostility in schizophrenia: a double-blind study 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans (LA) 2001"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0017|cit17","unstructured":"Citrome LL Volavka J Czobor P Sheitman BB Lindenmayer JP McEvoy JP Atypical antipsychotics and hostility in schizophrenia: a double-blind study 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA) 2002"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Czobor P Volavka J Sheitman B Lindenmayer JP Citrome L McEnvoy J Antipsychotic-induced weight gain and therapeutic response: a differential association Journal of Clinical Psychopharmacology 2002 244 51","DOI":"10.1097\/00004714-200206000-00003"},{"issue":"4","key":"10.1002\/14651858.CD009830.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1176\/jnp.2006.18.4.509","article-title":"Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder","volume":"18","author":"Hoptman","year":"2006","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009830.pub2-BIB0020|cit20","first-page":"S169","article-title":"Changes in glucose and cholesterol levels in schizophrenia patients treated with typical and atypical antipsychotics","volume":"5","author":"Lindenmayer","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009830.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0022|cit22","unstructured":"Lindenmayer JP Czobor P Volavka J Citrome LL Sheitman BB McEvoy JP Changes in glucose and cholesterol in schizophrenia treated with atypicals 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA) 2002"},{"issue":"4","key":"10.1002\/14651858.CD009830.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4088\/JCP.v65n0416","article-title":"Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia","volume":"65","author":"Lindenmayer","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0024|cit24","unstructured":"Lindenmayer JP Czobor P Volavka J Lieberman JA Citrome LL Sheitman BB Effects of atypicals on the syndromal profile in treatment-resistant schizophrenia 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco (CA) 2003"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0025|cit25","unstructured":"Lindenmayer JP Czobor P Yolayka J Lieberman JA McEvoy JP Citrome LL Do atypicals change the syndrome profile in treatment-resistant schizophrenia? 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans (LA) Marathon Multimedia 2001"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0026|cit26","unstructured":"Lindenmayer JP Volavka J Lieberman JA Citrome LL Sheitman B McEvoy JP Do atypicals change the syndromal profile in treatment-resistant schizophrenia? 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA) 2002"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009830.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"284S","DOI":"10.1016\/S0924-9338(00)94238-X","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia","volume":"15","author":"Mohr","year":"2000","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009830.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpsychires.2004.04.010","article-title":"Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder","volume":"39","author":"Nolan","year":"2005","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD009830.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009830.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.jcp.0000117424.05703.29","article-title":"Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"24","author":"Volavka","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0031|cit31","unstructured":"Volavka J Czobor P Sheitman B Lindenmayer JP Citrome L McEvoy J Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000"},{"issue":"12","key":"10.1002\/14651858.CD009830.pub2-BIB0032|cit32","first-page":"2132","article-title":"\"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder\": erratum","volume":"159","author":"Volavka","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009830.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009830.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2004.11.007","article-title":"Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with Nurses Observation Scale for inpatient evaluation","volume":"76","author":"Volavka","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0035|cit35","unstructured":"Lewis CF Haloperidol versus risperidone in the treatment of aggressive psychotic male inmates 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"issue":"11","key":"10.1002\/14651858.CD009830.pub2-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003082.pub3","article-title":"Haloperidol versus placebo for schizophrenia","author":"Adams","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009830.pub2-BIB0037|cit37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007445.pub2","article-title":"Chlorpromazine for psychosis induced aggression or agitation","author":"Ahmed","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD009830.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0039|cit39","unstructured":"American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia www.psychiatryonline.com\/content.aspx?aID=45971"},{"issue":"8","key":"10.1002\/14651858.CD009830.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD009830.pub2-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003729.pub2","article-title":"Olanzapine IM or velotab for acutely disturbed\/agitated people with suspected serious mental illnesses","author":"Belgamwar","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD009830.pub2-BIB0043|cit43","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0044|cit44","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2011"},{"issue":"3","key":"10.1002\/14651858.CD009830.pub2-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003441.pub2","article-title":"'As required' medication regimens for seriously mentally ill people in hospital","author":"Chakrabarti","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0046|cit46","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town 2000"},{"issue":"6","key":"10.1002\/14651858.CD009830.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD009830.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD009830.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD009830.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000525.pub2","article-title":"Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses","author":"Gibson","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009830.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003079.pub2","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","author":"Gillies","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0054|cit54","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1503","key":"10.1002\/14651858.CD009830.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"2505-18","DOI":"10.1098\/rstb.2008.0034","article-title":"Violent behaviour among people with schizophrenia: a framework for investigations of causes, and effective treatment, and prevention","volume":"363","author":"Hodgins","year":"2008","journal-title":"Philosophical Transactions of The Royal Society B Biological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD009830.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005146","article-title":"Haloperidol plus promethazine for psychosis-induced aggression","author":"Huf","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0057|cit57","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0058|cit58","unstructured":"Krakowski MI Clozapine and olanzapine in violent schizophrenics CRISP database (www-commons.cit.nih.gov\/crisp\/index.html)"},{"issue":"2-3","key":"10.1002\/14651858.CD009830.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD009830.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.brainresbull.2009.01.005","article-title":"The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice","volume":"79","author":"L\u00f3pez-Munoz","year":"2009","journal-title":"Brain Research Bulletin"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD009830.pub2-BIB0065|cit65","first-page":"327","article-title":"Treatment of acute agitation in psychotic disorders","volume":"26","author":"Mohr","year":"2005","journal-title":"Neuro endocrinology Letters"},{"issue":"3","key":"10.1002\/14651858.CD009830.pub2-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002084.pub2","article-title":"Containment strategies for people with serious mental illness","author":"Muralidharan","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0067|cit67","volume-title":"The Short-Term Management of Disturbed\/Violent Behaviour in Inpatient Psychiatric Settings and Emergency Departments","volume":"25","author":"National Institute for Clinical Excellence","year":"2005"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"10","key":"10.1002\/14651858.CD009830.pub2-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009377","article-title":"Haloperidol (rapid tranquilisation) for psychosis induced aggression or agitation","author":"Powney","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1-2","key":"10.1002\/14651858.CD009830.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S1742646408001234","article-title":"Establishing gold standard approaches to rapid tranquillisation: a review and discussion of the evidence of the safety and efficacy of medications used","volume":"4","author":"Pratt","year":"2008","journal-title":"Journal of Psychiatric Intensive Care"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0071|cit71","unstructured":"The Lundbeck Institute Psychotropics www.psychotropics.dk\/moleculeView\/default.aspx"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0072|cit72","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"2","key":"10.1002\/14651858.CD009830.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001163","article-title":"Seclusion and restraint for people with serious mental illnesses","author":"Sailas","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1192\/apt.bp.109.007310","article-title":"Management of acute agitation in psychosis: an evidence-based approach in the USA","volume":"17","author":"Schleifer","year":"2011","journal-title":"Advances in Psychiatric Treatment"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0075|cit75","first-page":"359","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011"},{"issue":"5","key":"10.1002\/14651858.CD009830.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD009830.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD009830.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.179.6.503","article-title":"Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia","volume":"179","author":"Xiberas","year":"2001","journal-title":"British Journal of Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009830.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T05:06:12Z","timestamp":1634792772000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009830.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,27]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009830.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,27]]}}}